Fatty Liver Response of Cardio-metabolic Risk Factors to Laser Acupuncture Versus Cupping

Non-alcoholic Fatty Liver Response of Cardio-metabolic Risk Factors to Laser Acupuncture Versus Cupping-with-scarification

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04971434

Enrollment

Registered

2021-07-21

Start date

2021-07-11

Completion date

2021-12-01

Last updated

2021-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fatty Liver

Brief summary

Every-two-week applied cupping (with scarification) session within one month on back of upper thorax is not compared previously regarding its effect on cardio-metabolic risk factors to the daily application of laser on acupoints (for month, except Fridays) in fatty liver patients. This trial will compare the two procedure effects on cardio-metabolic risk factors in fatty liver.

Detailed description

In fatty liver patients,every-two-week applied cupping (with scarification) session within one month on back of upper thorax for 30 patients will be compared regarding its effect on cardio-metabolic risk factors to the daily application of laser on acupoints (for month, except Fridays) of other 30 patients.

Interventions

DEVICElaser stimulation for acupoints

In fatty liver patients (30 patients), a daily application of 4-minute laser (for one month, except Fridays) on acupoint number 25,40,36 of stomach meridian, acupoint number 3 of liver meridian, acupoint number 6 of spleen meridian,acupoint number 9,12,4 of conception vessel meridian, acupoint number 14 of governor vessel meridian, acupoint number 4, 11 of large intestine meridian, acupoint number 34 of gall bladder meridian

OTHERcupping with scarification

In fatty liver patients (30 patients),every-two-week applied cupping (with scarification) session within one month on back of upper thorax

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

35 Years to 55 Years

Healthy volunteers

Inclusion criteria

* Diagnosed Fatty liver patients by ultrasonography * Class I obese patients

Exclusion criteria

* Cardiovascular and respiratory disorders/diseases. * Autoimmune disorders/diseases. * Pregnancy * Other liver disorders/diseases.

Design outcomes

Primary

Measure	Time frame	Description
high-density lipoprotein	It will be measured after 4 weeks of treatment	serum lipid
cholesterol	It will be measured after 4 weeks of treatment	serum lipid
triglyceride	It will be measured after 4 weeks of treatment	serum lipid
low-density lipoprotein	It will be measured after 4 weeks of treatment	serum lipid

Secondary

Measure	Time frame	Description
c reactive protein	It will be measured after 4 weeks of treatment	it will be measured in plasma
blood glucose	It will be measured after 4 weeks of treatment	fasting gluocse
blood pressure	It will be measured after 4 weeks of treatment	it will be measure with manual manometer
rate of pulse	It will be measured after 4 weeks of treatment	it will be measured at radial artery

Countries

Egypt

Contacts

Primary ContactAli Ismail, lecturer

allooka2012@gmail.com02 01005154209

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026